Company Overview

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for cancer, with an emphasis on systemic and localized delivery of oncolytic virotherapies. The company operates within the biotechnology and immuno-oncology sectors and is primarily focused on developing proprietary stem cell-based platforms designed to deliver therapeutic viruses to solid tumors while helping shield those viruses from immune clearance. Its core revenue profile is currently research and development driven, as the company remains in the clinical-development stage and does not yet generate material commercial product revenue based on publicly available filings.

Calidi’s primary business lines center on its stem cell-based delivery technologies and engineered viral therapeutics, including programs designed for high-grade glioma and metastatic solid tumors. The company positions itself through a differentiated approach that combines cell therapy with virotherapy, aiming to improve tumor targeting and systemic delivery efficiency. Calidi evolved through multiple corporate and financing transactions, including a public market listing transaction involving a special purpose acquisition company structure, after which the combined entity adopted the Calidi Biotherapeutics name and began trading on Nasdaq under the ticker CLDI.

Business Operations

Calidi conducts operations primarily through its immuno-oncology research and clinical development activities. Its programs include allogeneic stem cell platforms intended to transport oncolytic viruses directly to tumors, with product candidates targeting difficult-to-treat cancers. Key technology platforms include the company’s stem cell-based delivery systems and enveloped virotherapy approaches intended to improve persistence and biodistribution of therapeutic viruses. The company’s operations are concentrated in preclinical development, clinical trial execution, intellectual property development, and regulatory advancement.

The company’s activities are primarily based in the United States, with research, administrative, and clinical coordination functions centered in San Diego, California. Calidi collaborates with clinical institutions, contract research organizations, manufacturing partners, and academic centers to support development programs. Public disclosures identify proprietary technology assets and licensed intellectual property as important operational components. Data regarding large-scale international commercial operations remains inconclusive based on available public sources because the company is still in the clinical development stage.

Strategic Position & Investments

Calidi’s strategic direction is focused on advancing next-generation cancer immunotherapies that combine virotherapy and cell-based delivery technologies. Its growth initiatives include expanding clinical-stage programs, advancing systemic virotherapy platforms, and pursuing therapies capable of addressing metastatic disease and immune-resistant tumors. The company has emphasized the development of technologies intended to improve delivery of oncolytic viruses beyond localized injection approaches commonly used in earlier-generation therapies.

The company has also pursued strategic transactions and technology acquisitions intended to broaden its immunotherapy platform portfolio. Public filings and investor materials reference investments in proprietary delivery technologies, manufacturing capabilities, and intellectual property development. Calidi has highlighted emerging oncology fields such as systemic virotherapy, tumor-targeted viral delivery, and immune activation strategies as central to its long-term positioning. As a clinical-stage biotechnology company, its strategy remains heavily dependent on successful clinical development, regulatory progress, financing access, and partnership opportunities.

Geographic Footprint

Calidi Biotherapeutics is headquartered in San Diego, California, a major biotechnology and life sciences hub in the United States. The company’s operational footprint is primarily domestic, with clinical development, research coordination, and corporate activities concentrated in the U.S. Its clinical and research collaborations may involve institutions and vendors across multiple regions depending on study requirements and manufacturing arrangements.

While Calidi does not currently maintain the broad commercial infrastructure typical of large multinational pharmaceutical companies, its therapeutic programs are intended for global oncology markets. The company participates in sectors with international clinical relevance, particularly within North America and broader oncology research ecosystems. Publicly available information does not indicate a significant standalone commercial operating presence across multiple continents at this time.

Leadership & Governance

Calidi Biotherapeutics is led by executives with backgrounds in biotechnology, oncology, drug development, and corporate finance. Leadership has emphasized advancing innovative immunotherapy technologies through disciplined clinical development and strategic capital allocation. The company’s governance structure follows public-company reporting standards applicable to Nasdaq-listed biotechnology issuers, including oversight by a board of directors and executive management team.

Key executives identified in public filings and corporate disclosures include:

• Eric Poma – Chief Executive Officer
• Allan Camaisa – Executive Chairman
• Andrew Jackson – Chief Financial Officer
• Guy Travis Clifton – Chief Operating Officer

Public company disclosures, including SEC filings, investor presentations, and corporate governance materials, indicate that management’s strategic focus is centered on advancing clinical programs, strengthening intellectual property, securing financing for development activities, and pursuing differentiated approaches in immuno-oncology therapeutics.